Zabana Abdo, YamileMarín Jiménez, IgnacioRodríguez Lago, IagoVera, IsabelMartín Arranz, María DoloresGuerra, IvánGisbert, Javier P.Mesonero, FranciscoBenítez, OlgaTaxonera, CarlosPonferrada Díaz, ÁngelPiqueras, MartaLucendo, Alfredo J.Caballol, BertaMañosa, MíriamMartínez Montiel, PilarBosca Watts, MaiaGordillo, JordiBujanda, LuisManceñido, NoemíMartínez Pérez, TeresaLópez, AliciaRodríguez Gutiérrez, CristinaGarcía López, SantiagoVega, PabloRivero, MontserratMelcarne, LuigiCalvo, MaríaIborra, MarisaBarreiro de Acosta, ManuelSicilia, BeatrizBarrio, JesúsPérez Calle, José LázaroBusquets, DavidPérez Martínez, IsabelNavarro Llavat, MercèHernández, VicentArgüelles Arias, FedericoRamírez Esteso, FernandoMeijide, SusanaRamos, LauraGomollón, FernandoMuñoz, FernandoSuris, GerardOrtiz de Zarate, JoneHuguet, José MaríaLlaó, JordinaGarcía Sepulcre, Mariana FeSierra, MónicaDurà, MiguelEstrecha, SandraFuentes Coronel, AnaHinojosa, EstherOlivan, LorenzoIglesias, EvaGutiérrez, AnaVarela, PilarRull, NúriaGilabert, PauHernández Camba, AlejandroBrotons, AliciaGinard, DanielSesé, EvaCarpio, DanielAceituno, MontserratCabriada, José LuisGonzález Lama, YagoJiménez, LauraChaparro, MaríaLópez San Román, AntonioAlba, CristinaPlaza Santos, RocíoMena, RaquelTamarit Sebastián, SonsolesRicart, ElenaCalafat, MargalidaOlivares, SonsolesNavarro, PabloBertoletti, FedericoAlonso Galán, HoracioPajares, RamónOlcina, PabloManzano, PamelaDomènech, EugeniEsteve, MariaThe ENEIDA Registry of GETECCU2023-02-062023-02-062022-12-192077-0383https://hdl.handle.net/2445/193150(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.14 p.application/pdfengcc by (c) Zabana, Yamile et al., 2022http://creativecommons.org/licenses/by/3.0/es/COVID-19SARS-CoV-2Factors de risc en les malaltiesMalalties inflamatòries intestinalsCOVID-19SARS-CoV-2Risk factors in diseasesInflammatory bowel diseasesinfo:eu-repo/semantics/article2023-02-03info:eu-repo/semantics/openAccess